Replies to post #20485 on Amarin Corp Plc (AMRN)

[ranjo]

if you can convince Obama Vascepa will show reduced immediate costs of Obamacare it will be allowed, but all they see are increased pharmacy charges

if you can reduce stint procedures and hospital days it will be a no brainer ... exact sciences has a noninvasive molecular diagnostic that will be reimbursed at somewhere between $300-500 a test replacing FIT/FOBT at about $22 a test but it could save the cost of treating CRC in the screening population saving billions to CMS annually and of course lives, pain and suffering etc.